Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8105588 | 0.98 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL9528879 | 0.98 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL6004486 | 0.97 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL6007116 | 0.97 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL8103657 | 0.97 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL6006028 | 0.97 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL8103517 | 0.97 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL6004562 | 0.96 | AGTR1 (0.65) | AGTR1AGTR2 | |
| SCHEMBL6006878 | 0.95 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL6004681 | 0.95 | AGTR1 (0.64) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
| WO-2005016249-A2 | COMPOSITIONS OF A CHROMENE OR PHENYL ACETIC ACID CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ACE INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| JP-3098772-B2 | — | — | 2000-10-16 | — | — | JP | claimed |
| EP-0527851-B1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | SEARLE & CO (US) | 1998-12-23 | — | — | EP | claimed |
| EP-0527851-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | claimed |
| US-5098920-A | Hypotensive agents and treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 1992-03-24 | — | — | US | claimed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | claimed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | WEBB RANDY LEE | 2008-05-22 | — | — | US | disclosed |
| EP-1014989-B1 | ENDOTHELIN ANTAGONIST AND A RENIN-ANGIOTENSIN SYSTEM INHIBITOR AS A COMBINED PREPARATION | ABBOTT GMBH & CO KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| EP-0527851-B1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | SEARLE & CO (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5696116-A | TREATING DISORDERS ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0752249-A2 | Use of an angiotensin II antagonist and a benzofurane derivative having antiarithmic activity for the manufacture of a medicament for the treatment of cardiovascular disorders | SANOFI (FR) | 1997-01-08 | — | — | EP | disclosed |
| EP-0634175-A1 | Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-18 | — | — | EP | disclosed |
| EP-0527851-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5098920-A | Hypotensive agents and treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 1992-03-24 | — | — | US | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | AGTR1 2488/4885AGTR2 1977/4885 |
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | AGTR1 4/4885AGTR2 3/4885 |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | MME, REN, ACE | AGTR1 5/4885AGTR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.